According to Natera's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 9.73586. At the end of 2023 the company had a P/S ratio of 6.95.
Year | P/S ratio | Change |
---|---|---|
2023 | 6.95 | 30.2% |
2022 | 5.34 | -62.19% |
2021 | 14.1 | -35% |
2020 | 21.7 | 149.97% |
2019 | 8.69 | 158.42% |
2018 | 3.36 | 47.07% |
2017 | 2.29 | -19.06% |
2016 | 2.83 | -1.07% |
2015 | 2.86 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Vertex Pharmaceuticals VRTX | 10.3 | 5.84% | ๐บ๐ธ USA |
Prothena PRTA | 12.1 | 24.22% | ๐ฎ๐ช Ireland |
Paratek Pharmaceuticals
PRTK | 0.7621 | -92.17% | ๐บ๐ธ USA |